-
1.发明申请CYCLIZED PEPTIDOMIMETIC SMALL MOLECULE INHIBITORS OF THE WDR5 AND MLL1 INTERACTION 有权WDR5和MLL1相互作用的环化小分子抑制剂公开(公告)号：US20130150309A1
公开(公告)日：2013-06-13
申请号：US13686475
申请日：2012-11-27
Applicant: The Regents of the University of Michigan
Inventor： Shaomeng Wang , Hacer Karatas , Yali Dou , Elizabeth Townsend , Denzil Bernard , Fang Cao
IPC: C07K5/12 , A61N5/10 , C07D255/02 , A61K38/12 , A61K45/00
CPC classification number: C07K5/126 , A61K38/12 , A61K45/00 , A61K45/06 , A61N5/10 , A61N2005/1098 , C07D255/02 , C07K5/0207 , C07K5/021 , C07K5/0215 , C07K5/06034 , C07K5/0815 , C07K5/101 , C07K5/1019 , C07K5/123 , A61K2300/00
Abstract: Cyclic peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.
Abstract translation: 公开了抑制MLL1和WDR5之间相互作用的循环肽模拟物。 还公开了抑制MLL1活性的方法和治疗癌症的方法。
-
Patent Agency Ranking
公开(公告)号：US20210198237A1
公开(公告)日：2021-07-01
申请号：US17101323
申请日：2020-11-23
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Angelo Aguilar , Ke Zheng , Shilin Xu , Tianfeng Xu , Denzil Bernard , Liyue Huang
IPC: C07D401/14 , C07D401/04 , C07D405/04 , C07D211/34 , A61P35/00
Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
公开(公告)号：US10899738B2
公开(公告)日：2021-01-26
申请号：US16098147
申请日：2017-05-02
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Angelo Aguilar , Ke Zheng , Shilin Xu , Tianfeng Xu , Denzil Bernard , Liyue Huang
IPC: C07D401/14 , C07D401/04 , C07D405/04 , C07D211/34 , A61P35/00
Abstract: The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
4.发明授权Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction 有权环化的拟肽小分子抑制剂WDR5和MLL1相互作用公开(公告)号：US08980838B2
公开(公告)日：2015-03-17
申请号：US13686475
申请日：2012-11-27
Applicant: The Regents of the University of Michigan
Inventor： Shaomeng Wang , Hacer Karatas , Yali Dou , Elizabeth Townsend , Denzil Bernard , Fang Cao
IPC: A61K38/12 , A61P35/00 , C07K5/12 , A61K45/00 , A61N5/10 , C07D255/02 , C07K5/02 , C07K5/09 , C07K5/103 , C07K5/11 , C07K5/062 , A61K45/06
CPC classification number: C07K5/126 , A61K38/12 , A61K45/00 , A61K45/06 , A61N5/10 , A61N2005/1098 , C07D255/02 , C07K5/0207 , C07K5/021 , C07K5/0215 , C07K5/06034 , C07K5/0815 , C07K5/101 , C07K5/1019 , C07K5/123 , A61K2300/00
Abstract: Cyclic peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.
Abstract translation: 公开了抑制MLL1和WDR5之间相互作用的循环肽模拟物。 还公开了抑制MLL1活性的方法和治疗癌症的方法。
-
公开(公告)号：US12012467B2
公开(公告)日：2024-06-18
申请号：US16496974
申请日：2018-03-28
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Haibin Zhou , Jianfeng Lu , Liu Liu , Yi Sun , Denzil Bernard
IPC: A61K31/426 , A61K31/427 , A61K31/428 , A61K31/454 , A61K31/5377 , A61K38/05 , A61K38/06 , A61K38/07 , A61K45/06 , C07D277/30 , C07D277/64 , C07D417/12 , C07K5/02 , C07K5/062 , C07K5/078 , C07K5/097 , C07K5/113 , C07K5/117 , C07K7/02
CPC classification number: C07K5/1021 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/454 , A61K31/5377 , A61K38/05 , A61K38/06 , A61K38/07 , A61K45/06 , C07D277/30 , C07D277/64 , C07D417/12 , C07K5/02 , C07K5/021 , C07K5/06026 , C07K5/06139 , C07K5/0821 , C07K5/1024 , C07K7/02
Abstract: Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
-
公开(公告)号：US20190152947A1
公开(公告)日：2019-05-23
申请号：US16098147
申请日：2017-05-02
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor： Shaomeng Wang , Angelo Aguilar , Ke Zheng , Shilin Xu , Tianfeng Xu , Denzil Bernard , Liyue Huang
IPC: C07D401/14 , A61P35/00 , C07D401/04 , C07D405/04 , C07D211/34
Abstract: The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
-
-
-
-
-
Search Results
6
records
(took 0.015 seconds)
